Cancer in Renal Transplant Patients

Aleksandra M. De Golovine, Horacio E. Adrogue

Research output: Chapter in Book/Report/Conference proceedingChapter


In the current era of immunosuppression, renal transplantation is considered the gold standard for renal replacement therapy. In addition to excellent 1-year (95%), and 5-year (80%) graft survival, the mortality advantage over those remaining on dialysis makes it the therapy of choice. This success is due to the use of better immunosuppressant regimens that have prevented graft loss; however, it has resulted in the increased risk of infection and malignancy. In fact, the three most common causes of death of patients with a functioning kidney graft are cardiovascular, infectious and malignancy related.The increased risk of malignancy is thought to be multi-factorial. The issues include: (1) increased risk of genitourinary and thyroid malignancies related to chronic kidney disease; (2) immunosuppression that suppresses the immune system's tumor surveillance, promotes the development of pro-oncogenic viruses and intrinsically causes the development of malignancies, and (3) the spread of donor-derived malignancies via grafts.In this chapter, the above concepts will be explored and the most practical approaches will be offered to help the clinician screen for malignancy and manage immunosuppression in a post-kidney transplant recipient who is always at an increased risk for malignancy.

Original languageEnglish (US)
Title of host publicationRenal Disease in Cancer Patients
Number of pages16
ISBN (Print)9780124159488
StatePublished - Oct 2013


  • Chronic kidney disease
  • Donor graft complications
  • Immunosuppression
  • Malignancy
  • Pro-oncogenic viruses
  • Renal transplantation

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)


Dive into the research topics of 'Cancer in Renal Transplant Patients'. Together they form a unique fingerprint.

Cite this